Aviragen Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 79   

Articles published

AVIR 1.37 +0.01 (0.74%)
price chart
Biota Pharmaceuticals, Inc. Announces Name Change to Aviragen Therapeutics ...
ATLANTA, April 12, 2016 -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) today announced that the Company has changed its name to Aviragen Therapeutics, Inc., (“Aviragen Therapeutics”), a pharmaceutical company focused on the development of the next ...
Aviragen Therapeutics Completes Royalty Deal With HealthCare Royalty Partners ...
ATLANTA, April 25, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.) a pharmaceutical company that is developing the next generation of antivirals, today announced that it has signed a ...
Aviragen Therapeutics Inc (NASDAQ:AVIR) Stock Technicals Hit Extreme Weakness
This is a technical analysis stock rating for Aviragen Therapeutics Inc (NASDAQ:AVIR) . The company has a one bull technical rating which indicates extreme weakness.
Aviragen Therapeutics Provides Update on Phase 2a Trial of BTA585 for the ...
ATLANTA, May 26, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, today announced that it has voluntarily ...
Aviragen Therapeutics Halted, Pending News (NASDAQ:AVIR)  Sonoran Weekly Review
Aviragen Therapeutics, Inc. (NASDAQ:AVIR) Fundamental Star Rating Report
This is a fundamental star rating report for Aviragen Therapeutics, Inc. (NASDAQ:AVIR) . The Capital Market Laboratories Star Rating is an objective, quantifiable measure of a company's operating and financial condition.
Biota Pharmaceuticals Is Now Aviragen Therapeutics
Subsequent to our last update on Aviragen Therapeutics, the company has been busy attending and presenting at industry conferences.
Aviragen Therapeutics Inc Stock Momentum at Critical Inflection Point
This is a momentum stock rating analysis for Aviragen Therapeutics Inc (NASDAQ:AVIR) . The company has a three bull momentum rating which indicates an inflection point.
BRIEF-Aviragen Therapeutics resumes enrollment in phase 2a RSV challenge trial
Aviragen Therapeutics Inc says in addition to receiving MHRA and ethics committee approval to resume enrollment and dosing in phase 2A trial.
Aviragen Therapeutics licenses Georgia State Technology to develop antiviral ...
ATLANTA--The Georgia State University Research Foundation (GSURF) has entered into a licensing and sponsored research agreement with Aviragen Therapeutics, Inc., a Georgia-based pharmaceutical company developing the next generation of antivirals ...
Aviragen Therapeutics Announces Inducement Grant for New Employee
ATLANTA, July 01, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, announced today that the compensation ...